Drug Reimbursement In Brief From Pharma Earnings Calls
Executive Summary
Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...